Abstract:Objective: To summarize the conclusions of an expert panel of neurologists specializing in multiple sclerosis (MS) convened for the purpose of creating a treatment algorithm with regard to the clinical management of MS. The panel was sponsored by the Health Science Center for Continuing Medical Education and the University of Medicine and Dentistry of New Jersey and supported by an educational grant from Biogen Idec, Inc. Summary: MS is a chronic demyelinating disease characterized by a variable clinical course. Currently, there is no cure for MS, and the management of MS requires lifelong treatment with disease-modifying agents. Some patients respond well to therapy for many years, whereas others may have aggressive disease that is more difficult to manage. Hence, given the variable nature in the course of MS and patients. response to treatment, neurologists must individualize care for their patients. An MS treatment algorithm was recently developed by a panel of neurologists who are MS experts to provide community neurologists with best-practice protocols for treating and managing their MS patients. The panel of experts categorized MS into 3 different stages, with patients transitioning between the stages based on their response to therapy and disease progression. Stage I represents MS early in the progression of the disease, during which platform drug therapy is recommended (i.e., interferon beta-1b [IFNbeta-1b], IFNbeta-1a, or glatiramer acetate). The results of randomized, controlled clinical trials suggest that IFNbeta is the optimal choice for platform therapy. Despite treatment with platform therapy, it is common for patients to experience some ongoing symptoms and periodic exacerbations of the disease (annual relapse rate of 0.59 to 0.84 on treatment); such relapses should not be considered treatment failures and are best managed with steroids. Stage II represents acute breakthrough disease (i.e., when the clinical activity becomes more frequent or severe). This stage is best managed by the addition of pulse corticosteroids to the platform drug. Stage III represents continued breakthrough disease and is best managed by the addition of immunosuppressants to the platform drug. Conclusion: The MS treatment algorithm provides an educational resource for physicians. It should assist all health care professionals involved in the management of MS patients and enhance their ability to improve quality of life for these patients over the course of the disease.

Consensus Recommendations for Diagnosis and Treatment of Multiple Sclerosis: 2023 revision of The MENACTRIMS Guidelines

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

Differential diagnosis of suspected multiple sclerosis: an updated consensus approach

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Clinical practice guidelines for multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease 2023 in Japan

Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

Diagnosis and treatment of progressive multiple sclerosis: A position paper

Consensus recommendations for family planning and pregnancy in multiple sclerosis in argentina

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists

Multiple sclerosis. Recent modalities of treatment

The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement

ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis

[Treatments for multiple sclerosis: update]

Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis

Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Living Treatment Recommendations for the Management of Axial Spondyloarthritis

Approach to Managing the Initial Presentation of Multiple Sclerosis: A Worldwide Practice Survey

Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China

Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines

Consensus‐Based Guidelines for Communicating a Misdiagnosis of Multiple Sclerosis to Reduce Psychological Distress